1.	Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL) Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GEM012, NCT00407303
2.	Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GEM010, NCT00405951
3.	Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00252, 07-082, CDR0000561779, MSKCC-07082, 7937, NCT00521144
4.	Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Hodgkin Lymphoma or Non-Hodgkin Lymphoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000566357, U01CA062505, CCC-PHI-58, PHI-58, 7943, NCT00538187
5.	A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC) Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GEM017, NCT00682981
6.	Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00255, MC068A, CDR0000597950, N01CM62205, MAYO-MC068A, 7952, NCT00719901
7.	Phase I/II Randomized Study of Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: OSU-10040, OSU-10040, 8600, NCT01238146
8.	Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GEM011, NCT00359892
9.	Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GEM013, NCT00413114
10.	Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GEM014, NCT00427856
11.	Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML) Phase: Phase II Type: Treatment Status: Completed Age: 70 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GEM016, NCT00684918
12.	Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GX006, NCT00438178